Omeros (OMER) Common Equity (2010 - 2026)
Omeros' (OMER) quarterly Common Equity came in at -$63.3 million in Q1 2026, up 70.34% year-on-year from -$37.2 million in Q1 2025, and up 47.76% quarter-over-quarter from -$121.2 million in Q4 2025.
Omeros (OMER) Common Equity (2010 - 2026) Analysis & Trends
Omeros has disclosed Common Equity across 17 years of filings, most recently posting -$63.3 million for Q1 2026.
- Common Equity for Q1 2026 came in at -$63.3 million, up 70.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$63.3 million (up 70.34% YoY), and the FY2025 annual result was -$121.2 million, up 33.61% from the prior year.
- Common Equity came in at -$63.3 million for Q1 2026 at Omeros, up from -$121.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $85.7 million in Q4 2022 to a low of -$228.7 million in Q2 2025.
- The 5-year median for Common Equity is -$63.3 million (2026), against an average of -$78.9 million.
- Across the five-year window, Common Equity jumped 1215.45% in 2023 and sank 1005.02% in 2024, its largest moves.
- Omeros' Common Equity stood at $85.7 million in 2022, then plunged by 129.16% to -$25.0 million in 2023, then sank by 630.93% to -$182.6 million in 2024, then jumped by 33.61% to -$121.2 million in 2025, then jumped by 47.76% to -$63.3 million in 2026.
- The last three Common Equity figures came in at -$63.3 million (Q1 2026), -$121.2 million (Q4 2025), and -$220.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | -63.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.33 Mn |
| Dec 31, 2025 | -121.23 Mn |
| Sep 30, 2025 | -220.48 Mn |
| Jun 30, 2025 | -228.69 Mn |
| Mar 31, 2025 | -213.55 Mn |
| Dec 31, 2024 | -182.61 Mn |
| Sep 30, 2024 | -154.17 Mn |
| Jun 30, 2024 | -124.60 Mn |
| Mar 31, 2024 | -71.33 Mn |
| Dec 31, 2023 | -24.98 Mn |
| Sep 30, 2023 | -13.95 Mn |
| Jun 30, 2023 | 20.51 Mn |
| Mar 31, 2023 | 54.94 Mn |
| Dec 31, 2022 | 85.68 Mn |
| Sep 30, 2022 | -46.31 Mn |
| Jun 30, 2022 | -32.70 Mn |
| Mar 31, 2022 | -4.93 Mn |
| Dec 31, 2021 | 23.78 Mn |
| Sep 30, 2021 | -262.70 Mn |
| Jun 30, 2021 | -246.30 Mn |